Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder
NCT02158533Phase 3Completed
- Sponsor
- Alkermes
- Start
- May 2014
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of buprenorphine + samidorphan in major depressive disorder (MDD), sponsored by Alkermes. Started May 2014; status: completed.
02
Drugs
buprenorphine + samidorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02158533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02158533.